NovaBay Pharmaceuticals Extends CEO’s Employment Agreement Until 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN: NBY) recently disclosed in a Form 8-K filing lodged with the Securities and Exchange Commission that the Company and its Chief Executive Officer (CEO) and General Counsel, Justin M. Hall, have agreed to a contractual extension. The Third Amendment to Mr. Hall’s Executive Employment Agreement, initially dated January 31, 2020, and previously amended in 2021 and 2023, has been further amended to extend his term of employment until December 31, 2025, unless otherwise terminated.

The specifics of the Employment Agreement, along with its subsequent amendments, have been outlined in Exhibits accompanying the filing made by the Company. The Exhibits provide comprehensive details regarding the terms and conditions of Mr. Hall’s extended employment.

In other news related to the healthcare industry, Sanara MedTech Inc., a medical technology company based in Fort Worth, Texas, announced key executive appointments. Elizabeth Taylor has taken on the role of Chief Financial Officer, succeeding Michael McNeil, who has been appointed as Chief Accounting Officer and Chief Administrative Officer, effective as of January 15, 2025.

These appointments have been described as pivotal for Sanara’s growth and development. Ms. Taylor brings over 25 years of financial expertise to the position, having served in various key roles in the medical device industry, hedge funds, and private equity. Her appointment underscores Sanara’s commitment to strengthening its leadership team for future growth prospects.

Sanara MedTech Inc. focuses on developing and commercializing technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical, chronic wound, and skincare markets. The company offers a range of products in these sectors and provides virtual wound care and dermatology consultation services.

Investors and industry analysts are keeping a close eye on NovaBay Pharmaceuticals and Sanara MedTech Inc. as they navigate strategic appointments and operational developments in their respective fields. Market watchers anticipate that these moves could have implications for the companies’ growth trajectories and market positioning moving forward.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NovaBay Pharmaceuticals’s 8K filing here.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.